Coric Vlad — SEC Form 4 filings
SEC reporting owner CIK 1704317. 15 Form 4 filings on record with FilingPulse; latest filed 2026-06-08.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-01-10 to 2026-06-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 4 filings — 927,315 shares, $12,999,938 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 40.
- Largest priced transaction: purchase of 121,951 shares @ $41.00 ($4,999,991) in Biohaven Ltd., filed 2024-04-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Biohaven Ltd. (BHVN) | Chief Executive Officer, Director | 9 | 4 legs · 809,669 sh · $10,999,956 | — | 18 |
| Veradermics, Inc (MANE) | Director | 1 | 2 legs · 117,646 sh · $1,999,982 | — | 15 |
| Revance Therapeutics, Inc. (RVNC) | Director | 2 | — | — | 4 |
| Royalty Pharma plc (RPRX) | Director | 3 | — | — | 3 |
Form 4 filings — Coric Vlad
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-03-03 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 550,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Veradermics, Inc (MANE) | Conversion (C): 33,706 · Conversion (C): 33,706 · Conversion (C): 148,794 · Conversion (C): 148,794 · Conversion (C): 78,075 · Conversion (C): 78,075 · +11 more | EDGAR |
| 2026-01-07 | 4 | Biohaven Ltd. (BHVN) | Option exercise (M): 14,250 @ $0 · Tax withholding (F): 7,430 @ $9.93 · Option exercise (M): 14,250 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Biohaven Ltd. (BHVN) | Purchase (P): 333,333 @ $7.50 · Purchase (P): 333,333 @ $7.50 | EDGAR |
| 2025-05-14 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 7,614 @ $0 | EDGAR |
| 2025-04-21 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 3,184 @ $0 | EDGAR |
| 2025-02-06 | 4 | Revance Therapeutics, Inc. (RVNC) | Code (U): 5,784 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-01-07 | 4 | Biohaven Ltd. (BHVN) | Option exercise (M): 14,250 @ $0 · Tax withholding (F): 6,805 @ $38.64 · Grant/award (A): 343,000 (derivative) @ $0 · Grant/award (A): 57,000 (derivative) @ $0 · Option exercise (M): 14,250 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | Biohaven Ltd. (BHVN) | Purchase (P): 21,052 @ $47.50 | EDGAR |
| 2024-05-03 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-04-23 | 4 | Biohaven Ltd. (BHVN) | Purchase (P): 121,951 @ $41 | EDGAR |
| 2024-04-05 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 232 · Grant/award (A): 231 · Grant/award (A): 231 | EDGAR |
| 2024-03-08 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 2,162 · Grant/award (A): 2,155 · Grant/award (A): 2,155 | EDGAR |
| 2024-01-10 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 5,400 · Grant/award (A): 5,384 · Grant/award (A): 5,384 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-10 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1704317 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →